Menu
Close

About Us

About Us

   Tantti Laboratory Inc. (“Tantti”) was founded in 2014 by eight distinguished professors in Taiwan with expertise in Chemical and Materials Engineering. Since its inception, the company has developed two platform technologies (Tantti® Monolith and Tantti® BioScaffolds) which use microfluidics and in-mold polymerization to create highly ordered micro- and nano-porous biomaterials.

 

▪Tantti® Monolith represents a breakthrough in liquid chromatographic column technology used in the separation and purification of biological products, including proteins, antibodies, exosomes, and viral vectors. Its applications include the production of vaccines, biologic therapies, antibodies, etc.

 

▪Tantti® BioScaffolds, which includes our UniTantrix™ Microcarriers and 3D BioScaffold product lines, is our platform solution for the biomedical industry’s growing need for high-density cell production used in vaccine/viral particle production, cell therapy, tissue engineering,  regenerative medicine, and high-throughput/content drug screening, among other applications.

 

    Our technologies have received patent approvals around the world, including in the United States, Europe, Japan, Taiwan and China, and we continue to conduct extensive R&D in-house as well as with our academic and corporate research  partners.

 

   At Tantti, our mission is not only to develop innovative biomaterial technologies that provide the highest performing, cost- and time-effective solutions for our customers.  We also aim to become a collaborative partner with our customers, assisting them in realizing their visions of developing innovative biologic therapies, whether it is in a small-scale research setting or at the commercial production stage.  We distribute our products around the world, both directly to customers and through our distribution partners.

 

 Ultimately, we hope our commitment to innovation, quality, and service will drive Tantti’s long-term sustainable growth in the biomaterials industry. Together with our partners, we strive to become a world-class, global biomaterials company and we sincerely welcome you to collaborate with us, whether as a customer, distributor, research partner, employee or as an investor/shareholder.

 

 

 

Time Line Company History

2014
12
Company founded
2015
09
Company headquarters relocated to Taoyuan City, Taiwan
11
Completion of laboratory facility in Taoyuan City
2017
01
Signed exclusive licensee agreement with Academia Sinica of Taiwan
10
Received grant from the Taiwan Innovation and Entrepreneurship Center (TIEC)
2018
01
Signed joint R&D agreement with NanoMicro, Co,.Ltd.
02
Participated in 4th International Medical Expo & Conference - Medical Japan 2018
04
Participated in the American Association for Cancer Research (AACR) Annual Meeting 2018
06
Completed capital raise with the National Development Fund of Taiwan, Harbinger Venture Management, and China Steel
09
Received grant from the Taoyuan Small Business Innovation Research (SBIR) program
10
Signed cooperation agreement with National Health Research Institutes of Taiwan
11
Participated in the 2018 Taiwan Healthcare Expo
2019
02
Participated in the 5th International Medical Expo & Conference - Medical Japan
03
Participated in the 2019 Pittcon Conference & Expo
03
Completion of second laboratory and production facility in Taoyuan City
06
Received grant from Taiwan’s Ministry of Science and Technology (MOST)
07
Signed distribution agreement with MBL Beijing Biotech Co., Ltd. (a JSR Life Sciences company) for distribution of Tantti products in China
2020
02
Participated in the 6th International Medical Expo & Conference - Medical Japan
03
Signed R&D cooperation agreement with Tosoh Corporation (Japan)
06
Selected for and participated in the 3rd Merck Accelerator China program
07
Renewed distribution agreement with MBL Beijing Biotech Co., Ltd.
07
Signed innovation project cooperation agreement with Merck KGaA’s Innovation Hub (China)
12
Completed filing of public registration with the Taiwan SEC
2021
02
Signed distribution agreement with In Vitro Technologies Pty Ltd. (Australia & New Zealand)